6 October 2021 in Journal of Gastrointestinal Cancer
1 December 2018 in Prostate International
Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant response to targeted therapy by DCs pulsed with prostate-specific membrane antigen was evaluated, and the possible adverse effects of this modality were investigated. Major databases were searched up to Feb 2017, to identify studies in which the antitumor efficacy of DCs pulsed with the extracellular portion of PSMA was studied for the treatment of mCRPC. Data were collected by two reviewers and analyzed using Comprehensive Meta-Analysis software, version 2.0. Our study consisted of 6 nonrandomized prospective (cohort) trials, overall reporting on 153 mCRPC patients. The event rate that is the representative of fraction of patients showing antitumor response was 0.43 (95% confidence interval = 0.355-0.512; P = 0.097). No significant between-study heterogeneity or inconsistency was detected (I2 = 5.47; Q = 5; P = 0.382). Our study failed to demonstrate a significant therapeutic efficacy for DCs in mCRPC. However, no significant adverse effects were seen.
1 January 2024 in Russian Journal of Electrochemistry
Gastric cancer (GC) is one of the considered enormously important cancer types in the world. A large number of mortality rates have revealed that there is a massive shortage in the prognosis and treatment of GC because the majority of GC cases are identified at an advanced stage. In this regard, the rapid platform for non-invasive detection of GC cells through the analysis of GC biomarkers in the first stages with high sensitivity is essential for the success in the treatment of GC. In recent years, different types of electrochemical immunosensors as efficient sensing devices with benefits including accuracy, reproducibility and low cost have played an extremely significant role in the monitoring of GC. One of the significant issues in the development of electrochemical immunosensors is to increase the system’s sensitivity. A variety of nanomaterials based on carbon-based, silica-based and metallic-based nanomaterials have been used as sensing platforms on the different types of electrochemical electrodes for improving the properties of biodevices. This review highlighted the new progress and technical breakthroughs comprising electrochemical immunosensor for the determination of GC biomarkers including CA19-9, CA72-4, CA125 and CEA. In diverse matrices and proved how nanoprobes could enhance the performance of electrochemical immunsensing approaches.
1 September 2019 in Asian Pacific Journal of Cancer Prevention
AAAli Akabr Movassaghpour Akbari
Ali Akabr Movassaghpour Akbari
+1
Background: The key proliferative RTKs for AML include c-KIT receptor (CD117) and FLT-3 receptor (CD135).The aim of this study was to evaluate the CD135 and CD117 expression, co-expression of CD135 and CD117(CD135+CD117), and the association of that co-expression with Event Free Survival (DFS) and Overall Survival (OS)rates. Material and Methods: We analyzed CD117 and CD135 expression on AML blasts by flow cytometry and itsassociation with Event Free Survival (DFS) and Overall Survival (OS) in 66 AML treated on Hematology-OncologyResearch Center, Iran, Tabriz. Results: The overall OS and EFS were 50% and 80.3% respectively during our study.Cox-regression analysis revealed that a poor EFS was significantly associated a low CD135 (HR 0.34, 95% CI0.13–0.88, P = 0.02). Conclusion: This is the first study from Iran to show that the expressions of CD135, CD117 iseasily measurable by routine diagnostic flow-cytometry, and CD135+117 were not significantly associated with CR,EFS, or OS .